Having agreed to help out CureVac NV with its mRNA-based coronavirus vaccine, Bayer AG has been speaking about the challenges it needs to address in manufacturing vaccines for humans for the first time in its 157-year history.
Bayer Confident CureVac COVID Pact Will Be A Success
Plans To Deliver mRNA Vaccine On Track
CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.
More from COVID-19
More from Scrip
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.